PALI Insider Trading Activity and SEC Form 4 Filings
PALI insider trading summary
Over the past 12 months, insiders at Palisade Bio, Inc. (PALI) reported 10 open-market purchases worth $297K by 2 insiders and 4 sales worth $420K by 2 insiders on SEC Form 4. Net insider selling was $123K.
Latest PALI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Donald Allen Williams | Director | Buy | $15K (10,000 @ $1.46) |
| Oct 1, 2026 | Donald Allen Williams | Director | Buy | $14K (10,000 @ $1.42) |
| Jul 9, 2026 | Robert Baltera Jr. | Director | Buy | $49K (25,000 @ $1.96) |
| Jul 8, 2026 | Robert Baltera Jr. | Director | Buy | $40K (20,000 @ $1.99) |
| Jul 7, 2026 | Robert Baltera Jr. | Director | Buy | $61K (30,000 @ $2.03) |
| Jul 7, 2026 | John David Finley | CEO, CFO | Sell | $303K (146,798 @ $2.07) |
| Jul 7, 2026 | Mitchell Lawrence Jones | Chief Medical Officer | Sell | $107K (51,880 @ $2.05) |
| Jul 6, 2026 | Robert Baltera Jr. | Director | Buy | $41K (20,000 @ $2.05) |
| Jul 2, 2026 | Robert Baltera Jr. | Director | Buy | $20K (10,000 @ $1.98) |
| Jul 1, 2026 | Robert Baltera Jr. | Director | Buy | $40K (20,000 @ $1.98) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.